PTP Announces Partnership with TetraScience to Accelerate Innovation in Therapeutics
PTP, a leading cloud consultancy firm specializing in the life sciences industry, is pleased to announce its partnership with TetraScience, the Scientific Data Cloud company and a pioneer in supporting customers in harmonizing scientific data. This collaboration aims to accelerate and improve the drug discovery and development process, optimize data-driven decision-making, and ultimately improve patient outcomes.
PTP has a proven track record of successfully guiding biotechnology companies through the complex landscape of pipeline workflows for drug discovery and development. With TetraScience’s innovative scientific data cloud, PTP will offer services that empower biopharmaceutical companies to harness the full potential of their scientific data.
The Tetra Scientific Data Cloud(™) enables seamless integration of disparate data sources, providing a unified view of critical information for scientific teams. This partnership will allow PTP’s clients to leverage TetraScience’s expertise in data collection, centralization, and harmonization to streamline workflows, accelerate decision-making, and improve collaboration across interdisciplinary teams.
“We are thrilled to partner with TetraScience, a company that shares our passion for innovation and excellence in the life sciences industry,” said Ethan Simmons, Managing Partner of PTP. “Their groundbreaking technology will enable us to provide unparalleled solutions to our clients, helping them make data-driven decisions and ultimately bring life-saving treatments to patients faster.”
Chad Garrett, Chief Revenue Officer, TetraScience, said, “PTP’s deep AWS and life sciences knowledge, along with commitment to client success make them an ideal partner for TetraScience. By combining our respective strengths, we can empower companies in the therapeutics space to overcome the challenges of leveraging scientific data and accelerating the pace of drug discovery and development.”
The partnership between PTP and TetraScience is expected to have a significant impact on the therapeutics industry by unlocking the potential of scientific data to drive innovation and improve patient outcomes. Clients can expect to benefit from the combined expertise and resources of two industry leaders, enabling them to navigate the complex and rapidly evolving landscape of drug discovery and development with confidence.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more